

UCLA

UCLA Previously Published Works

Title

Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

Permalink

<https://escholarship.org/uc/item/5f66t9gj>

Journal

PLOS ONE, 17(10)

ISSN

1932-6203

Author

Editors, The PLOS ONE

Publication Date

2022

DOI

10.1371/journal.pone.0276650

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

CORRECTION

Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer


The *PLOS ONE* Editors

Notice of republication

This article was republished on October 10, 2022, to correct an error. Please download this article again to view the correct version.

Reference

1. Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, et al. (2021) Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. *PLoS ONE* 16(12): e0261994. <https://doi.org/10.1371/journal.pone.0261994> PMID: 34941969



OPEN ACCESS

Citation: The *PLOS ONE* Editors (2022) Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. *PLoS ONE* 17(10): e0276650. <https://doi.org/10.1371/journal.pone.0276650>

Published: October 20, 2022

Copyright: © 2022 The PLOS ONE Staff. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.